Uroplasty To Participate In The Craig-Hallum Alpha Select Conference
MINNEAPOLIS, Sept. 19, 2013 /PRNewswire/ — Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the Craig-Hallum 4(th) Annual Alpha Select Conference on Thursday, September 26, 2013. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 10:55am ET and meet with investors one on one at the conference in New York City.
Attendance at the conference is by invitation only. A live webcast of the presentation will be broadcast via the Internet. Those interested in joining the webcast may access it through Uroplasty’s website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days following the event.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom is a global medical company committed to offering transformative treatment options to specialty physicians. Our products are designed to help providers change the lives of their voiding dysfunction patients and strengthen the efficiency of their practices. Our focus is the continued commercialization of our Urgent(®) PC Neuromodulation System, the only FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique(®), an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.
For Further Information:
Brett Reynolds, SVP and CFO
Jenifer Kirtland (Investors)/Janine McCargo (Business Media)
SOURCE Uroplasty, Inc.